On July 3, the Department of Health and Human Services released its 2026 plan for regulatory actions, which includes a proposed Food and Drug Administration (FDA) rule on “Transparency in Direct-to-Consumer Advertising.”
As NMA previewed in response to September 2025 statements released by the FDA and the White House, the proposed rule seeks to close the “adequate provision loophole” that allows broadcast direct-to-consumer prescription drug advertisements to disclose “risk, contraindication, and other safety information in another source” outside of the advertisement. This exemption is also utilized on digital advertising.
The rule could serve as a de-facto ban on DTC prescription drug advertising if drafted broadly enough to make obligatory disclosures appear in length that is cost and time prohibitive for advertisers. While not an outright ban on DTC advertising, the rule has significant speech implications.
The FDA aims to publish the proposed rule by December 2026, with final rulemaking in mid-2027.
NMA is active in a broader advertising coalition and is developing an engagement strategy. We welcome further member input on how the rule could impact publisher revenue.
